Drug intelligence / Profile preview

Sh1002

Development stage: Discontinued
Lead developer: China Shenghuo Pharmaceutical Holdings
Modality: Small Molecules

Overview

**Sh1002** is an investigational drug developed by China Shenghuo Pharmaceutical Holdings, Inc. for treating retinal vascular lesions, a complication of diabetes mellitus. It is in early preclinical or early clinical development stage, as evidenced by the submission of an Investigational New Drug (IND) application. Limited public data is available on its mechanism of action, chemical structure, or detailed pharmacology, but it targets diabetic retinopathy-related vascular pathology.

Beyond the preview

Go deeper on Sh1002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sh1002.

Explore the full profile